ReviewDiabetes, obesity & metabolism2022
Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan.
Review in Diabetes, obesity & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 154 citations in OpenAlex.
- Intensive Blood Pressure Control and Cardiovascular Outcomes Across Cardiovascular-Kidney-Metabolic Syndrome Stages: A Post Hoc Analysis of the China Rural Hypertension Control Project.JAMA network open · 2026Trial
- A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes.Journal of diabetes investigation · 2026Trial
- Association between body roundness index and progression of cardio-renal-metabolic diseases using multistate models.GeroScience · 2026Article
- Cellular Senescence in Diabetic Cardiomyopathy: Mechanistic Insights and Therapeutic Perspectives.Cardiovascular drugs and therapy · 2026Review
- Early signs of nephropathy in adolescents with obesity.International journal of obesity (2005) · 2026Article
- Insulin resistance surrogate indices and incident cardiovascular disease across cardiovascular-kidney-metabolic stages 0-3: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Cumulative visceral fat burden and progression to advanced cardiovascular kidney metabolic syndrome in Chinese middle-aged and older adults.Scientific reports · 2026Article
- Food inflammation index and risks of all-cause and cardiovascular mortality among individuals with cardiovascular-kidney-metabolic syndrome: a nationally representative cohort study from NHANES 1999-2018.Scientific reports · 2026Article
- Developmental origins and environmental determinants of cardiovascular-kidney-metabolic syndrome: A pediatric precision prevention perspective.Biomedical journal · 2026Review
- Association of dietary niacin intake with cardiovascular-kidney-metabolic syndrome risk and mortality.American journal of preventive cardiology · 2026Article
- Association of Triglyceride-Glucose-Frailty Index with Cardiovascular Disease and All-Cause Mortality Incidence in Individuals with Cardiovascular-Kidney-Metabolic Syndrome Stages 0-3: A Nationwide Prospective Cohort Study.Journal of clinical medicine · 2026Article
- Longitudinal associations of cumulative and repeated-measure patterns of insulin resistance surrogate indices with biological age acceleration and incident cardiovascular disease across cardiovascular-kidney-metabolic syndrome stages 0-3: evidence from CHARLS 2011-2020.Cardiovascular diabetology · 2026Article
- Accelerometer-derived "weekend warrior" physical activity pattern and trajectory of cardio-renal-metabolic multimorbidity: a multi-state analysis in the UK Biobank.BMC public health · 2026Article
- Impact of renal function on antidiabetic drug selection in Japan: A real-world analysis using the J-DREAMS database.Journal of diabetes investigation · 2026Article
- Arterial stiffness and incident chronic kidney disease risk: a two-phase retrospective cohort study.BMC nephrology · 2026Article
- Association Between Depressive Symptoms and Incidence of Stroke in a Population With Cardiovascular-Kidney-Metabolic Syndrome Stages 0 to 3: Nationwide Prospective Cohort Study.Interactive journal of medical research · 2026Article
- Associations of Socioeconomic Status With Cardiorenal Metabolic Multimorbidity: Evidence From the UK Biobank Cohort.JACC. Advances · 2026Article
- Atherogenic Index of Plasma Predicts the Onset and Progression of Cardio-Renal-Metabolic Multimorbidity: Evidence From a Nationwide Prospective Cohort Study.Journal of diabetes · 2026Article
- Triglyceride-glucose index and mortality in critically ill patients with cardiovascular-kidney-metabolic syndrome stage 4.Cardiovascular diabetology · 2026Article
- Association of the estimated glucose disposal rate combined with a body shape index with all-cause and cardiovascular-specific mortality among individuals with cardiovascular-kidney-metabolic syndrome.Cardiovascular diabetology · 2026Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insights from epidemiological, clinical and basic research are illuminating the interplay between metabolic disorders, cardiovascular disease (CVD) and kidney dysfunction, termed cardio-renal-metabolic (CRM) disease. Broadly defined, CRM disease involves multidirectional interactions between metabolic diseases such as type 2 diabetes (T2D), various types of CVD and chronic kidney disease (CKD). T2D confers increased risk for heart failure, which-although well known-has only recently come into focus for treatment, and may differ by ethnicity, whereas atherosclerotic heart disease is a well-established complication of T2D. Many people with T2D also have CKD, with a higher risk in Asians than their Western counterparts. Furthermore, CVD increases the risk of CKD and vice versa, with heart failure, notably, present in approximately half of CKD patients. Molecular mechanisms involved in CRM disease include hyperglycaemia, insulin resistance, hyperactivity of the renin-angiotensin-aldosterone system, production of advanced glycation end-products, oxidative stress, lipotoxicity, endoplasmic reticulum stress, calcium-handling abnormalities, mitochondrial malfunction and deficient energy production, and chronic inflammation. Pathophysiological manifestations of these processes include diabetic cardiomyopathy, vascular endothelial dysfunction, cardiac and renal fibrosis, glomerular hyperfiltration, renal hypoperfusion and venous congestion, reduced exercise tolerance leading to metabolic dysfunction, and calcification of atherosclerotic plaque. Importantly, recognition of the interaction between CRM diseases would enable a more holistic approach to CRM care, rather than isolated treatment of individual conditions, which may improve patient outcomes. Finally, aspects of CRM diseases may differ between Western and East Asian countries such as Japan, a super-ageing country, with potential differences in epidemiology, complications and prognosis that represent an important avenue for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.